UV Blood Irradiation for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

UV Blood Irradiation for Health & Longevity

Created on 08/10/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Ultraviolet light is applied to a small share of blood, then returned. Effects appear to come from changed immune cell behaviour, not direct microbe killing. The hospital version, adding a light-sensitizing drug, shows response in steroid-resistant disease, almost all from studies without comparison groups. The clinic version rests on reports without comparison groups. Nothing has been measured in healthy people. (Full Review)

Protocol

The classical extracorporeal protocol
50–100 mL
5–7% of blood volume, historically 1.5 mL per pound; quartz cuvette under a 254 nm ultraviolet C lamp for seconds to a few minutes, reinfused immediately
Course length and frequency
6–10 sessions
1–3 sessions per week for the initial series, then monthly maintenance if a response is perceived; historical acute-infection use was 1–3 sessions total
The drug-assisted hospital protocol
1–2 J/cm² ultraviolet A
8-methoxypsoralen at approximately 200 ng/mL added to apheresis-collected white cells; two consecutive days per cycle, cycles every 1–2 weeks initially
Time to effect
Graft-versus-host response
3–4 months
Drug-assisted hospital form; improves further by 6–8 months, so several cycles precede any judgement
Historical acute infection
24–76 hours
Fever resolution described after a single treatment in uncontrolled mid-century case series
Classical, subjective change
1–3 sessions
Described by clinics; no objective marker has been shown to change on any defined timeline in a controlled setting

Benefits

Contraindications
  • Porphyria of any type
  • Idiosyncratic reaction to psoralen compounds
  • Aphakia
  • Pregnancy and breastfeeding
  • Active melanoma
  • Light-sensitive autoimmune disease (systemic lupus erythematosus), albinism (drug-assisted version)
  • Strong caution: G6PD deficiency, hemoglobin below 10 g/dL, platelets below 20,000/µL, white cells below 1,000/µL, weight below 40 kg, estimated filtering capacity below 30 mL/min/1.73 m²
  • Strong caution: cardiovascular instability (myocardial infarction within 90 days, uncontrolled arrhythmia, New York Heart Association Class IV heart failure)
  • Strong caution: active untreated infection requiring antimicrobial therapy
    •
Key Interactions
  • Photosensitizing prescription medications: doxycycline, ciprofloxacin, amiodarone, hydrochlorothiazide, chlorpromazine, voriconazole
  • Over-the-counter photosensitizers: tretinoin, ibuprofen, glycolic acid
  • Photosensitizing supplements: St. John's wort, Ginkgo biloba, high-dose niacin
  • Antioxidant supplements: high-dose vitamin C, N-acetylcysteine, alpha-lipoic acid, glutathione
  • Oxidative therapies: ozone therapy, intravenous high-dose vitamin C, hyperbaric oxygen
  • Anticoagulants and antiplatelet agents: warfarin, apixaban, rivaroxaban, clopidogrel, aspirin
  • Systemic immunosuppressants and immunotherapy: tacrolimus, cyclosporine, prednisone, ruxolitinib, pembrolizumab, nivolumab

Risk & Side Effects

  • High: Vascular access and bloodstream infection risk; photosensitivity of skin and eyes after drug-assisted sessions; hemodynamic and citrate-related reactions during extracorporeal circulation
  • Medium: Hemolysis and red cell damage; cytopenias and infection susceptibility with repeated drug-assisted sessions; delay or displacement of effective treatment
  • Low: Transient symptom flare after treatment; autoimmune disease flare
  • Speculative: Long-term genotoxic and malignancy risk; interference with vaccination or immunotherapy response; impairment of oxygen transport at higher doses

Monitoring

Marker Target Why
G6PD enzyme activity Normal per assay reference Deficiency turns an oxidative challenge into hemolysis
Haptoglobin 50–150 mg/dL Falls first when red cells rupture; most sensitive early hemolysis marker
Lactate dehydrogenase 140–200 U/L Rises with red cell destruction and general cell turnover
Complete blood count with differential Hemoglobin 13.5–15.0 g/dL (men), 12.5–14.5 g/dL (women); lymphocytes 20–40% Red cell floor and white cell baseline the mechanism targets
High-sensitivity C-reactive protein Below 0.5 mg/L General inflammation marker most likely to move if the immune claim holds
Ferritin 50–125 ng/mL (men), 40–100 ng/mL (women) Distinguishes iron-deficient anemia from treatment-related red cell loss
Comprehensive metabolic panel, including calcium and creatinine Calcium 9.2–10.0 mg/dL; estimated filtering capacity above 90 mL/min/1.73 m² Predicts tolerance of citrate anticoagulation
Antinuclear antibody Negative Screens for light-sensitive autoimmune contraindications
Hepatitis B, hepatitis C, and HIV serology Negative or documented status Required by any facility handling blood outside the body

Cadence: Haptoglobin, lactate dehydrogenase, and complete blood count within 48 hours of the first session, after the third, and at the end of the initial series; high-sensitivity C-reactive protein and complete blood count then every 3 months if sessions continue; comprehensive metabolic panel every 6 months.

Qualitative Assessment

  • Daytime energy and afternoon crash frequency, scored 1–10 at a fixed time each day
  • Sleep quality and total sleep duration, ideally from a wearable rather than recall
  • Frequency and duration of minor infections over rolling 3-month windows
  • Post-session symptoms — chills, aching, fever, fatigue — and how long they take to resolve
  • Exercise capacity at a fixed workload, such as heart rate at a set pace or power output
  • Joint stiffness and general pain scores, where inflammation is the target
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.